BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

Registration

Registration

NCT05161429

Acronym

BESTMED

Study type

OBSERVATIONAL

Status

UNKNOWN

Enrollment

550000

Start

2021-07-01

Primary completion

2024-06-30

Lead sponsor

Brigham and Women's Hospital

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG:DPP4; DRUG:GLP-1 receptor agonist; DRUG:Basal Insulin; DRUG:SLGT2; DRUG:SU

Results posted

FALSE

Individual participant data sharing

NO

Registered primary outcomes

• 4-point major adverse cardiac events (MACE) [Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years.]
• 3-point major adverse cardiac events (MACE) [Follow-up begins 30 days after enrollment and ends at the earliest of a) the first study outcome; b) study end or c) loss to follow-up. Maximum duration of follow-up will be 10.5 years.]